BioXcel Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09075P1057
USD
2.09
0.22 (11.76%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Champions Oncology, Inc.
NanoString Technologies, Inc.
C4 Therapeutics, Inc.
Compugen Ltd.
BioAtla, Inc.
BioXcel Therapeutics, Inc.
Jasper Therapeutics, Inc.
Kezar Life Sciences, Inc.
Athira Pharma, Inc.
Turnstone Biologics Corp.
Affimed NV
Why is BioXcel Therapeutics, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is BioXcel Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
BioXcel Therapeutics, Inc.
-67.97%
-0.05
1722.51%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
13.34%
EBIT Growth (5y)
1.75%
EBIT to Interest (avg)
-44.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
39.64%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.12
EV to EBIT
-1.74
EV to EBITDA
-1.75
EV to Capital Employed
-5.63
EV to Sales
46.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -55.77 MM

NET PROFIT(HY)

Higher at USD -27.95 MM

-20What is not working for the Company
NET SALES(HY)

At USD 0.29 MM has Grown at -82.92%

RAW MATERIAL COST(Y)

Grown by 160.95% (YoY

CASH AND EQV(HY)

Lowest at USD 49.59 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.09 times

INTEREST(Q)

Highest at USD 4.22 MM

PRE-TAX PROFIT(Q)

Lowest at USD -19.48 MM

NET PROFIT(Q)

Lowest at USD -19.48 MM

Here's what is working for BioXcel Therapeutics, Inc.
Operating Cash Flow
Highest at USD -55.77 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Here's what is not working for BioXcel Therapeutics, Inc.
Net Sales
At USD 0.29 MM has Grown at -82.92%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -19.48 MM has Fallen at -102.76%
over average net sales of the previous four periods of USD -9.61 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -19.48 MM has Fallen at -102.76%
over average net sales of the previous four periods of USD -9.61 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest
Highest at USD 4.22 MM
in the last five periods and Increased by 5.74% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit
Lowest at USD -19.48 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -19.48 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 49.59 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio
Lowest at 2.09 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 160.95% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales